COMMUNIQUÉS West-GlobeNewswire

VitalHub Announces Intention to Enter the Patient Flow Market Through Acquisition Strategy

21/02/2019 - 18:44

TORONTO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce that it has imminent plans to enter the rapidly growing global patient flow market through a [...]

iCAD to Showcase ProFound AI™ Solution for Digital Breast Tomosynthesis at ECR 2019

21/02/2019 - 17:12

Currently pending CE Mark, ProFound AI technology for 2D mammography will also be previewed NASHUA, N.H., Feb. 21, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing [...]

AroCell AB (publ) Year-End Report 2018

21/02/2019 - 08:30

Word from the CEO ”2018 has been an exciting year for AroCell with several major events. In April, AroCell signed a global non-exclusive license agreement with F. Hoffmann-La Roche Ltd (Roche). Roche is the market [...]

Ossur Hf : Final agenda and proposals for the Annual General Meeting 7 March 2019

21/02/2019 - 08:01

Announcement no. 12/2019 21 February 2019 Final agenda and proposals Enclosed is the final agenda and proposals for Össur's Annual General Meeting to be held on Thursday 7 March 2019. The meeting will be held at Össur's [...]

Saniona publishes its year-end report for 2019

21/02/2019 - 08:00

PRESS RELEASE February 21, 2019 Financial highlights Jan – Dec 2018 (Jan - Dec 2017) Net revenues were SEK 54.9 M (20.7 M) EBIT was SEK -54.2 M (-57.2 M) Net profit/loss was SEK -41.1 M (-49.2) Earnings per share were [...]

VALNEVA Reports Strong 2018 Results, Expects Further Growth and Major Pipeline Progression in 2019

21/02/2019 - 07:01

Valneva Reports Strong 2018 Results, Expects Further Growth and Major Pipeline Progression in 2019 Major R&D milestones achieved in 2018, double-digit product sales revenue growth delivered; Lyme and chikungunya [...]

VALNEVA publie de très bons résultats 2018, prévoit une poursuite de la croissance et des avancées R&D importantes en 2019

21/02/2019 - 07:01

Valneva publie de très bons résultats 2018, prévoit une poursuite de la croissance et des avancées R&D importantes en 2019 Avancées R&D majeures et croissance à deux chiffres du chiffre d'affaires des ventes de [...]

Biocartis Group NV: BIOCARTIS TO HOST WEBCAST FOR ANNOUNCEMENT 2018 FINANCIAL RESULTS ON 28 FEBRUARY 2019

21/02/2019 - 07:01

PRESS RELEASE : REGULATED INFORMATION 21 February 2019, 07:00 CET BioCARTIS to Host Webcast FOR ANNOUNCEMENT 2018 FINANCIAL Results on 28 FEBRUARY 2019 Mechelen, Belgium, 21 February 2019 - Biocartis Group NV (the ' [...]

HealthEquity to Present at Investor Conferences

20/02/2019 - 23:29

DRAPER, Utah, Feb. 20, 2019 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY), the largest independent HSA custodian, today announced that it plans to participate at the following upcoming investor conferences: BTIG [...]

Akorn Comments on Fresenius’ Proposed Amended Claims

20/02/2019 - 23:25

LAKE FOREST, Ill., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX) today announced that it strongly contests Fresenius’ proposed amended claims filed earlier today. Akorn believes these claims are meritless [...]

Mesoblast Reports Financial Results and Operational Highlights for the First Half Ended December 31, 2018

20/02/2019 - 23:16

Strong cash reserves as Company prepares for potential US launch of remestemcel-L MELBOURNE, Australia and NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported its [...]

Hoth Therapeutics Inc. Announces Closing of Initial Public Offering

20/02/2019 - 23:15

NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Hoth Therapeutics Inc. (NASDAQ: HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as [...]

Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine

20/02/2019 - 23:05

Publication Highlights Safety and Efficacy Profile of Sacituzumab Govitecan Addressing High Unmet Need in Metastatic Triple-Negative Breast Cancer MORRIS PLAINS, N.J., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc [...]

MannKind Presents New Scientific Data at 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)

20/02/2019 - 23:00

WESTLAKE VILLAGE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced additional positive Afrezza clinical data to be presented in an oral presentation on Thursday, February 21, [...]

PLx Pharma Inc. Announces Completion of $15 Million Convertible Preferred Stock Financing

20/02/2019 - 22:55

HOUSTON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“ PLx ” or the “ Company ”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ [...]

GenMark Diagnostics to Participate in Upcoming Investor Conferences

20/02/2019 - 22:55

CARLSBAD, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to [...]

Adamas to Present at Two Upcoming Investor Conferences

20/02/2019 - 22:50

EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, [...]

Adamas to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 4, 2019

20/02/2019 - 22:49

EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2018 financial results on Monday, March 4, 2019 [...]

Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2018 Financial Results on February 28, 2019

20/02/2019 - 22:30

BURLINGTON, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2018 financial results after the close of the U.S. [...]